Chemiesynth Vapi Q1 Results: Net Loss Widens To ₹58.4 Lakh
Chemiesynth (Vapi) Ltd posted a Q1FY26 net loss of ₹58.37 lakh on revenue of ₹419.69 lakh. The Board approved raising authorized capital to ₹18.25 crore and issuing ₹15 crore in unlisted 5% NCRPS. The AGM is set for September 30, 2026.
*this image is generated using AI for illustrative purposes only.
Chemiesynth (Vapi) Limited reported a widened net loss of ₹58.37 lakh for the quarter ended June 30, 2026, compared to a loss of ₹45.63 lakh in the corresponding quarter of FY25. This deterioration occurred despite a modest rise in revenue from operations, which grew 5.6% year-on-year to ₹419.69 lakh from ₹397.46 lakh. The expanding loss signals continued operational pressure as the company navigates its financial performance in the early part of FY26.
The Board of Directors approved these unaudited financial results on August 12, 2026, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The results were subjected to a limited review by the statutory auditors, Manoj Shah & Co., who issued an unqualified report. The financial statements were prepared in accordance with Ind AS 34 and Section 133 of the Companies Act, 2013.
Financial Performance
While top-line growth was recorded, profitability remained under strain due to elevated expenses. Total income stood at ₹421.55 lakh, but total expenses reached ₹479.92 lakh, resulting in a pre-tax loss of ₹58.37 lakh. There was no tax expense recorded for the period.
| Particulars | Q1FY26 (₹ Lakh) | Q4FY26 (₹ Lakh) | Q1FY25 (₹ Lakh) | Change (YoY) |
|---|---|---|---|---|
| Revenue From Operations | 419.69 | 550.25 | 397.46 | +5.6% |
| Other Income | 1.86 | 1.35 | - | - |
| Total Income | 421.55 | 551.60 | 397.46 | +6.1% |
| Total Expenses | 479.92 | 497.12 | 443.09 | +8.3% |
| Net Profit / (Loss) | -58.37 | 60.36 | -45.63 | Wider Loss |
| EPS (Basic) (₹) | -1.90 | 1.97 | -1.49 | - |
Key expense drivers included cost of materials consumed at ₹192.34 lakh and other expenses at ₹235.87 lakh. Employee benefits expense remained stable at ₹75.43 lakh, while finance costs increased slightly to ₹28.11 lakh from ₹25.09 lakh in the prior year quarter.
Capital Raise and Preference Shares
In a move to strengthen its capital base, the Board approved increasing the authorized share capital from ₹3.25 crore to ₹18.25 crore. This involves an increase in equity shares and the introduction of preference shares. The proposal requires shareholder approval via a Special Resolution at the ensuing Annual General Meeting (AGM).
Additionally, the Board approved the issuance of unlisted Non-Convertible Cumulative Redeemable Preference Shares (NCRPS) on a private placement basis. Key terms include:
- Amount: Up to ₹15 crore (1,50,00,000 shares of ₹10 face value each).
- Coupon Rate: 5% per annum (cumulative).
- Tenure: 7 years from allotment.
- Listing: Unlisted.
- Redemption: Fully redeemable after 7 years; call and put options exercisable after 2 years.
- Security: Unsecured.
What the Numbers Show
The divergence between revenue growth (+5.6%) and expense growth (+8.3%) highlights margin compression in Q1FY26. While revenue improved sequentially from Q4FY26 levels where it was ₹550.25 lakh, the current quarter's lower revenue combined with high fixed costs like employee benefits and depreciation contributed to the loss. The company’s decision to raise ₹15 crore through NCRPS suggests a strategic focus on bolstering liquidity without diluting existing equity holders immediately, though it will incur cumulative dividend obligations.
Corporate Actions
The 40th Annual General Meeting is scheduled for September 30, 2026, at 11:00 AM at the registered office in Vapi. The cut-off date for remote e-voting is September 23, 2026. CS Nitin Sarfare has been appointed as the scrutinizer for the AGM. The Board also approved the related party transactions and the Directors' Report.
Historical Stock Returns for Chemiesynth Vapi
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| 0.0% | 0.0% | +15.73% | +105.57% | +115.84% | +441.47% |
How will the 5% cumulative dividend obligation on the new ₹15 crore NCRPS issuance impact Chemiesynth's cash flow and profitability in subsequent quarters?
What specific operational strategies is management implementing to address the margin compression caused by expenses growing faster (8.3%) than revenue (5.6%)?
Will the proceeds from the preference share issuance be allocated towards debt reduction or working capital, and how might this alter the company's financial leverage profile?
16
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
